1. In Vivo
  2. >>Archive

Medtronic Buys Sofamor Danek

Although the acquisition of Sofamor Danek by Medtronic came as a surprise to some, both Medtronic and Sofamor Danek had in recent years begun to move toward a common ground around neurosurgery. Sofamor Danek should benefit from Medtronic's growing presence in neurological medicine, especially surrounding minimally invasive and image-guided neurosurgery. In announcing the deal. Medtronic noted that its neurological business will, with Sofamor's revenues included, account for 28% of the company's overall sales this year, a figure Medtronic expects to grow to 40% in the next ten years.

Just three years ago, the spinal market was something of an orthopedic backwater: small, off the beaten path, an interesting place to play but one that much bigger, mainstream orthopedic companies tended to look at only from a safe distance. The high risk of litigation, significant technology differences, and a completely separate customer base made whatever potential synergies existed with a traditional orthopedic implant business pale before the obstacles.

The spinal market is now highly consolidated, with much of the recent acquiring done by large suppliers, not all of them orthopedic players. The purchase last year of AcroMed Corp.by...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

Final Chance To Have Your Say: Take Our Reader Survey This Week

 
• By Eleanor Malone

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Early Development Deals: Ipsen's Strategy For Biomarker-Driven Success

 
• By Eliza Slawther

Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.   

Shape Our Content: Take The Reader Survey

 
• By Eleanor Malone

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access In Vivo, or if you love it how it is, now is the time to have your voice heard.

In Partnership with Cerba Research

Prioritizing Safety in CAR-T Therapy: Patient Monitoring with Cerba Research’s Testing Portfolio

The cell and gene therapy (CGT) clinical trial landscape in general and CAR-T cell clinical trials in particular are a special focus for the FDA, EMA, and other regulatory agencies. The whole industry is thus aware of the recent FDA safety investigation and requirements for labeling CAR therapy products.

More from In Vivo

Medtech Innovators Court London-Based Investors At BioWales 2025

 
• By Ashley Yeo

BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

UK Bets On Regulatory Innovation As Competitive Advantage In Synthetic Biology

 
• By David Wild

The UK government has prioritized synthetic biology and created a "concierge service" for biotechs just as the US cuts science funding.